Compare CHEF & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CHEF | GPCR |
|---|---|---|
| Founded | 1985 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Distributors | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 3.8B |
| IPO Year | 2011 | 2023 |
| Metric | CHEF | GPCR |
|---|---|---|
| Price | $110.45 | $38.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 12 |
| Target Price | $76.33 | ★ $103.17 |
| AVG Volume (30 Days) | 712.6K | ★ 755.9K |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.27 | N/A |
| EPS | ★ 0.40 | N/A |
| Revenue | ★ $1,301,520,000.00 | N/A |
| Revenue This Year | $8.66 | N/A |
| Revenue Next Year | $7.83 | N/A |
| P/E Ratio | $273.23 | ★ N/A |
| Revenue Growth | ★ 9.11 | N/A |
| 52 Week Low | $53.24 | $20.04 |
| 52 Week High | $117.65 | $94.90 |
| Indicator | CHEF | GPCR |
|---|---|---|
| Relative Strength Index (RSI) | 49.16 | 27.86 |
| Support Level | $105.39 | $36.11 |
| Resistance Level | $116.31 | $41.50 |
| Average True Range (ATR) | 3.66 | 2.45 |
| MACD | -0.89 | -1.11 |
| Stochastic Oscillator | 15.24 | 2.07 |
The Chefs' Warehouse Inc is a specialty food distributor in metropolitan areas across the United States, the Middle East and Canada. The company's product portfolio is comprised of imported and local specialty food products such as cheese, cooking oils, chocolates, dried food, baking products, meats, and other food products. It operates via one reporting segment called Food Product Distribution. Operations are concentrated on the east, midwest, and west coasts of the U.S. The company provides service to restaurants, clubs, hotels, caterers, schools, bakeries, casinos, and specialty food stores.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.